Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy: Table 1.

Abstract

Seizures are a well-recognized symptom of primary brain tumors, and anticonvulsant use is common. This paper provides an overview of epilepsy and the use of anticonvulsants in glioma patients. Overall incidence and mechanisms of epileptogenesis are reviewed. Factors to consider with the use of antiepileptic drugs (AEDs) including incidence during the disease trajectory and prophylaxis along with considerations in the selection of anticonvulsant use (ie, potential side effects, drug interactions, adverse effects, and impact on survival) are also reviewed. Finally, areas for future research and exploring the pathophysiology and use of AEDs in this population are also discussed.

Postoperative seizure control in patients with tumor‐associated epilepsy

“…In particular, enzyme inducing AEDs, such as phenytoin and carbamazepine, are now generally avoided as first line options. 35,39 The major limitation of this study is its retrospective nature and small, heterogeneous sample. In addition, topiramate, lacosamide, valproate and zonisamide [36][37][38] have all shown various levels of benefit in small, uncontrolled studies.…”

“…Though overall, it is well appreciated that the literature is lacking in high quality studies comparing the efficacy of AEDs for tumor associated epilepsy. 35,39 The major limitation of this study is its retrospective nature and small, heterogeneous sample. Accounting for tumor progression is inherently difficult to perform in retrospective analyses.…”

Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma

“…First, as epilepsy commonly develops among GBM patients (17), it may aid a reduction in the severity and number of epileptic episodes and alleviate the requirement for anti-epileptic drugs, which are associated with detrimental neuropsychological effects and often interfere with the therapeutic regimen (18,19). Second, KD may increase the efficacy of cancer therapy.…”

Seizures in patients with cancer

“…Primary brain tumors present with seizures at a higher rate than metastases, and lower grade tumors (grade I or II) present with seizures at a higher rate than higher-grade Cancer April 1, 2020 tumors (grade III or IV). 26,28 The higher incidence of seizures at presentation in low-grade primary brain tumors was first observed clinically by Bailey and Cushing in 1926 29 and today is considered a favorable prognostic factor for a patient with a newly diagnosed primary brain tumor. 30 Multiple mechanisms have been proposed to explain the higher incidence of seizures in low-grade primary brain tumors.…”